Third Security

Fitnet Corporation is a mobile fitness application developer based in Blacksburg, Virginia, established in 2013. The company offers a unique platform that combines video workout sessions with biometric feedback, utilizing a device's webcam to analyze users' performance in real-time. Fitnet's application encompasses various fitness disciplines, including yoga, strength training, cardio, and mind/body practices. By scoring individual workout performance, Fitnet delivers a personalized fitness experience, enabling users to receive guidance from certified personal trainers and connect with workout partners online. Since its launch in 2014, the application has reached users in over 190 countries, facilitating substantial engagement in fitness activities, as evidenced by the collective burning of over 10 million calories by its clients.

Heyo, Inc. is a technology company that specializes in providing tools for social media marketing, particularly on Facebook. Founded in 2010 and based in Blacksburg, Virginia, the company offers a range of products designed to help businesses create engaging Facebook fan pages, contests, sweepstakes, and mobile-optimized landing pages. Heyo's software features intuitive drag-and-drop builders and templates that enable users to easily customize their online presence and campaigns across various platforms. The company emphasizes mobile compatibility, allowing for seamless integration of content on mobile devices. As an industry leader in mobile app development, Heyo also facilitates the creation of apps that can publish across mobile, Facebook, and the web, making it simpler for businesses to connect with their customers and enhance their online engagement.

Transgenomic, Inc. is a global biotechnology company that specializes in the purification and analysis of nucleic acids for the life sciences industry, focusing on molecular genetics and diagnostics. The company offers a range of genetic variation analytical services targeted at medical research, clinical, and pharmaceutical markets. It operates three main divisions: Transgenomic Clinical Laboratories, which provides molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract research laboratory supporting pre-clinical and clinical trials for oncology drugs; and Transgenomic Diagnostic Tools, which develops equipment and reagents for molecular testing and cytogenetics. Renowned for its leadership in cardiac genetic testing, Transgenomic's flagship C-GAAP test identifies gene mutations linked to cardiac disorders. The company has a global reach, serving customers in over 50 countries, including academic institutions, medical facilities, and pharmaceutical companies. By continually innovating and acquiring new technologies, Transgenomic aims to enhance its position in personalized medicine and capitalize on growth opportunities across its business divisions.

AmpliPhi Biosciences is a biopharmaceutical company that specializes in developing bacteriophage-based therapies for bacterial infections. By utilizing naturally occurring viruses known as bacteriophages, the company aims to address various bacterial infections, particularly those caused by drug-resistant strains prevalent in hospital environments. AmpliPhi has established a drug development and manufacturing platform that enables the rapid creation and production of multiple phage-based therapies. The company’s initial focus is on treating acute and chronic infections affecting the lungs, sinuses, and gastrointestinal tract. With operations in Richmond, Virginia, Colworth Science Park near London, and outside Sydney, Australia, AmpliPhi is committed to advancing its pipeline of phage therapies to effectively combat targeted bacterial diseases.

Soligenix, Inc., a late-stage biopharmaceutical company based in Princeton, New Jersey, focuses on developing and commercializing treatments for rare diseases and serious side effects of cancer therapies, where there is an unmet medical need. The company operates through two segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops therapies such as SGX301 for cutaneous T-cell lymphoma, SGX942 for oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone for gastrointestinal disorders. The Public Health Solutions segment works on biodefense vaccines and therapeutics, including RiVax, a ricin toxin vaccine, and SGX943, a therapeutic candidate for antibiotic-resistant and emerging infectious diseases.

Precigen is a biotechnology company focused on developing synthetic biology solutions. It specializes in designing, building, and regulating gene programs, with its technologies applicable across various end markets. The company's approach involves forming exclusive collaborations with partners who possess specific industry expertise and resources in development, sales, and marketing. This model allows Precigen to commercialize its innovations effectively, bringing new and improved products and processes to market. Its operations are divided into segments, including biopharmaceuticals and Exemplar, and the company generates revenue through technology access fees, royalties, and milestone payments from these collaborations.

Precigen is a biotechnology company focused on developing synthetic biology solutions. It specializes in designing, building, and regulating gene programs, with its technologies applicable across various end markets. The company's approach involves forming exclusive collaborations with partners who possess specific industry expertise and resources in development, sales, and marketing. This model allows Precigen to commercialize its innovations effectively, bringing new and improved products and processes to market. Its operations are divided into segments, including biopharmaceuticals and Exemplar, and the company generates revenue through technology access fees, royalties, and milestone payments from these collaborations.

Synchrony Ventures, established in 2016, is the early-stage venture capital arm of Synchrony Financial, a leading U.S. consumer financial services company. Based in San Francisco, the firm invests in innovative, early-stage companies within the financial services, healthcare, and commerce sectors, aligning with Synchrony's core business areas. Synchrony Ventures provides not only capital but also expertise, partnership, and access to Synchrony's extensive network, helping portfolio companies achieve their unique ambitions.

Cyntellect is dedicated to setting new standards in cell analysis, purification, and processing technology. Cyntellect's products support key applications to advance life science research, biopharmaceutical production, stem cell research and drug discovery. The Company's technology employs in situ, microplate-based cytometry to analyze cells with minimal sample manipulation, and process cells with great precision and efficiency. Cyntellect's expanding cellular analysis and processing portfolio is expected to play an enabling role in the coming age of advanced cell-based diagnostics and therapeutics.

Cyntellect is dedicated to setting new standards in cell analysis, purification, and processing technology. Cyntellect's products support key applications to advance life science research, biopharmaceutical production, stem cell research and drug discovery. The Company's technology employs in situ, microplate-based cytometry to analyze cells with minimal sample manipulation, and process cells with great precision and efficiency. Cyntellect's expanding cellular analysis and processing portfolio is expected to play an enabling role in the coming age of advanced cell-based diagnostics and therapeutics.

Precigen is a biotechnology company focused on developing synthetic biology solutions. It specializes in designing, building, and regulating gene programs, with its technologies applicable across various end markets. The company's approach involves forming exclusive collaborations with partners who possess specific industry expertise and resources in development, sales, and marketing. This model allows Precigen to commercialize its innovations effectively, bringing new and improved products and processes to market. Its operations are divided into segments, including biopharmaceuticals and Exemplar, and the company generates revenue through technology access fees, royalties, and milestone payments from these collaborations.

LevelVision designs and deploys video display technologies, and provides marketing solutions to the place-based, ambient, and out-of-home marketing industries.

Synchrony Ventures, established in 2016, is the early-stage venture capital arm of Synchrony Financial, a leading U.S. consumer financial services company. Based in San Francisco, the firm invests in innovative, early-stage companies within the financial services, healthcare, and commerce sectors, aligning with Synchrony's core business areas. Synchrony Ventures provides not only capital but also expertise, partnership, and access to Synchrony's extensive network, helping portfolio companies achieve their unique ambitions.

Precigen is a biotechnology company focused on developing synthetic biology solutions. It specializes in designing, building, and regulating gene programs, with its technologies applicable across various end markets. The company's approach involves forming exclusive collaborations with partners who possess specific industry expertise and resources in development, sales, and marketing. This model allows Precigen to commercialize its innovations effectively, bringing new and improved products and processes to market. Its operations are divided into segments, including biopharmaceuticals and Exemplar, and the company generates revenue through technology access fees, royalties, and milestone payments from these collaborations.

Diffusion Pharmaceuticals Inc. is a clinical-stage biotechnology company based in Charlottesville, Virginia, focused on developing innovative therapies for life-threatening medical conditions. The company's lead product candidate, transcrocetinate sodium (TSC), aims to enhance oxygen delivery to hypoxic tissues, addressing complications associated with various severe health issues. TSC is currently in Phase III clinical trials for glioblastoma multiforme and Phase II trials for metastatic brain cancer and acute stroke. Additionally, Diffusion is working on RES-529, a PI3K/Akt/mTOR pathway inhibitor that has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development for oncology applications, primarily targeting glioblastoma. The company also has a research collaboration with the University of Virginia Health and the Integrated Translational Research Institute of Virginia to explore TSC's efficacy in patients suffering from acute respiratory distress syndrome related to COVID-19. Founded in 2001, Diffusion Pharmaceuticals is dedicated to addressing critical health challenges through its advanced therapeutic candidates.